Medical Therapy of Colorectal Cancer in the Biomarker Era
|
|
- Hollie Chandler
- 6 years ago
- Views:
Transcription
1 Medical Therapy of Colorectal Cancer in the Biomarker Era Axel Grothey Professor of Oncology Mayo Clinic College of Medicine Rochester, Minnesota Disclosures Consulting activities (honoraria went to the Mayo Foundation) Amgen Bayer Pfizer Roche/Genentech BMS Imclone/Eli Lilly Eisai/Morphotek I WILL include discussion of investigational or off-label use of a product in my presentation. Learning Objectives Describe the key practice changes for management of stage III and IV colorectal cancer (CRC) and critical targeted therapy additions to the treatment armamentarium for metastatic CRC Become familiar with the unique side effect profiles of the targeted agents used to treat metastatic colorectal cancer and best management strategies advanced practitioners can implement to support patients on therapy Identify means to improve collaboration among oncologists and advanced practitioners in oncology 1
2 Advances in the Treatment of Stage IV CRC Best supportive care (BSC) 5-FU Irinotecan Capecitabine Oxaliplatin Cetuximab Panitumumab median overall survival Treatment Paradigms for mcrc Some patients with stage IV disease can be cured by an interdisciplinary approach In the palliative setting: FOLFOX = XELOX = FOLFIRI (XELIRI has problems with toxicity) The addition of biologics to chemotherapy has improved outcomes, but not as much as we had hoped We are on the verge of individualized therapy based on molecular predictive factors A high number of agents is currently available for the treatment of mcrc 5-FU Capecitabine Irinotecan Oxaliplatin Cetuximab Regorafenib Aflibercept Panitumumab 2
3 ESMO Guidelines 2012 Schmoll. Ann Oncol 2012 Until 2012, Biologic Agents in Colorectal Cancer = Monoclonal Antibodies Fab Fc Murine Ab momab (17-1A) Chimeric Mouse-Human Ab ximab Cetuximab Humanized Ab zumab EGFR VEGF Human Ab mumab Panitumumab Nomenclature of Monoclonal Antibodies -mab monoclonal antibody -mo-mab mouse mab -xi-mab chimeric mab -zu-mab humanized mab -mu-mab human mab -tu-xx-mab tumor-directed xx mab -li-xx-mab immune-directed xx mab -ci-xx-mab cardiovascular-directed xx mab -vi-xx-mab virus-directed xx mab Inf-li-xi-mab Beva-ci-zu-mab Ri-tu-xi-mab Pani-tu-mu-mab 3
4 PlGF VEGF-B VEGF-A Y Ramucirumab Y VEGF-C, VEGF-D Aflibercept (VEGF Trap) Functions VEGF-R1 (Flt-1) Migration Invasion Survival VEGF-R2 (KDR/Flk-1) Proliferation Survival Permeability VEGF-R3 (Flt-4) Lymphangiogenesis Conclusion Anti-VEGF Therapy Duration of VEGF-inhibition matters Treatment to progression Maintenance strategies Treatment beyond progression Clinical synergism between FP + bevacizumab Positive distinguishing factors for aflibercept vs BEV in 2 nd line Tx not clear Head-to-head comparison? BEV combinable with FOLFOXIRI (TRIBE) No predictive biomarker identified! Ligand mabs Target Tumor Cell-Bound EGFR EGF-R Extracellular PTEN PI3K Akt Ras Raf MEK Intracellular MAPK Cell survival Proliferation DNA Angiogenesis Cell Motility Metastasis 4
5 Ligand mabs Target Tumor Cell-Bound EGFR EGF-R Extracellular PTEN PI3K Akt Ras Raf MEK Intracellular MAPK Cell survival Proliferation DNA Angiogenesis Cell Motility Metastasis NCIC CTG CO.17: Randomized Phase III Trial in mcrc Cetuximab vs. BSC (no crossover) KRAS mut KRAS wild-type All patients BSC n=83 Cetux n=81 BSC n=113 Cetux n=117 BSC n=285 Cetux n=287 RR 0% 1.2% 0% 12.8% 0% 6.6% PFS (mo) OS (mo) Karapetis et al. NEJM < < < CRYSTAL Study (1st Line) FOLFIRI + Cetuximab N = 599 EGFR-expressing metastatic CRC R PFS Stratified by: Regions ECOG PS FOLFIRI N = 599 Primary Endpoint: PFS (independent review) Secondary Endpoints: RR, DCR, OS, Safety, QoL Sample Size: 1217 patients randomized, ITT: 1198 pts Van Cutsem et al. NEJM
6 PFS estimate 5-FU/LV/IRI (FOLFIRI) ± Cetuximab: PFS Non-KRAS Adjusted Van Cutsem et al, 2009 FOLFIRI + Cetuximab FOLFIRI Subgroup effect No benefit HR = P = vs 8.9 mo PFS (mo) Number of patients FOLFIRI +/- Cetuximab PFS in Patients With KRAS wt Tumors Probability of PFS FOLFIRI FOLFIRI FOLFIRI + cetuximab FOLFIRI (n=350) FOLFIRI + cetuximab (n=316) No of events Median PFS 8.4 months 9.9 months [95% CI] [ ] [ ] HR [95% Cl] p-value [ ] Time (months) FOLFIRI + cetuximab van Cutsem et al., JCO 2011 Proportion Event-Free 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% PRIME (FOLFOX +/- Panitumumab) PFS by KRAS Mutation Status Final Analysis WT KRAS MT KRAS Months Proportion Event-Free 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Months Panitumumab + FOLFOX4 Median (mo) (95% CI) 10.0 ( ) FOLFOX4 8.6 ( ) HR = 0.80 (95% CI: ) Log-rank p-value = 0.01 Panitumumab + FOLFOX4 Median (mo) (95% CI) 7.4 ( ) FOLFOX4 9.2 ( ) HR = 1.27 (95% CI: ) Log-rank p-value = 0.02 Douillard et al., JCO
7 Mutations Beyond KRAS Codon 12/13 KRAS EXON 1 EXON 2 EXON 3 EXON % % 6% NRAS EXON 1 EXON 2 EXON 3 EXON 4 BRAF NT = not tested EXON % EXON NT 8% % NT 17% additional mutations in KRAS and NRAS! Douillard et al., NEJM 2013 Hazard Ratios for RAS Subgroups Potential detriment Douillard et al., NEJM 2013 FIRE-3 Phase III Study Design mcrc 1st-line therapy KRAS wild-type N= 592 Randomize 1:1 FOLFIRI + Cetuximab Cetuximab: 400 mg/m2 i.v. 120 min initial dose i m 00 a b : 4 m g / m i. v. 120 m i n i n i t i a l d o s e 2250 m mg/m g / m 2 2 i.v. i. v min m in q 1w 1 w q FOLFIRI + : 5 mg/kg i.v min q 2w FOLFIRI: 5-FU: 400 mg/m2 (i.v. bolus); folinic acid: 400 mg/ m 2 irinotecan: 180 mg/m 2 5-FU: 2,400 mg/m2 (i.v. 46h) Primary objective: Overall response rate (ORR) (inv assessed) Designed to detect a difference of 12% in ORR induced by FOLFIRI + cetuximab (62%) as compared to FOLFIRI + bevacizumab (50%) 284 evaluable patients per arm needed to achieve 80% power for a one-sided Fisher's exact test at an alpha level of 2.5% Heinemann et al., ASCO
8 FIRE-3 ORR Primary Endpoint FOLFIRI + Cetuximab FOLFIRI + ORR % 95% CI % 95% CI ITT population (N = 592) Odds ratio p Assessable for response (N = 526) p = Fisher's exact test (one-sided) Heinemann et al., ASCO 2013 Probability of survival FIRE-3 PFS Events n/n (%) FOLFIRI + Cetuximab 250/297 (84.2%) FOLFIRI + 242/295 (82.0%) Median (months) % CI HR 1.06 (95% CI ) Log-rank p= Months since start of treatment Number s at risk Heinemann et al., ASCO 2013 FIRE-3 Overall Survival Probability of survival PFS FOLFIRI + Cetuximab FOLFIRI + Events n/n (%) 158/297 (53.2%) 185/295 (62.7%) Median (months) % CI HR 0.77 (95% CI: ) Log-rank p = Number s at risk Split of curves Months since start of treatment Heinemann et al., ASCO
9 FIRE-3 Overall Survival Probability of survival FOLFIRI + Cetuximab FOLFIRI + Who are these pts? Analysis of RAS, PIK3CA, BRAF, PTEN, EGFR ligands Months since start of treatment Number s at risk Heinemann et al., ASCO 2013 FIRE-3 Update: Tested Mutations KRAS wt exon 2 subset KRAS EXON 1 EXON 2 EXON 3 EXON wt % 4.9% NRAS EXON 2 EXON 3 EXON 4 BRAF EXON % 2% EXON % 10% % 15% additional RAS mutations! % Summary of Results 14 RR months PFS * KRAS ex2 wt RAS wt RAS mut BRAF mut 0 KRAS ex2 wt RAS wt RAS mut BRAF mut OS months * * FOLFIRI + Cetuximab FOLFIRI + BEV * significant 5 0 KRAS ex2 wt RAS wt RAS mut BRAF mut Heinemann et al., ECC
10 Probability of survival FIRE-3 ESMO/ECCO Update Overall Survival All-RAS* wild type Events n/n (%) FOLFIRI + Cetuximab 91/171 (53.2%) FOLFIRI + 110/171 (64.3%) Median (months) 95% CI HR 0.70 (95% CI: ) p (log-rank)= Median Δ = 7.5 months 0.0 No. at 171 risk months since start of treatment Heinemann et al., ECC 2013 RAS* wild-type: KRAS 61/146; NRAS Exon2, NRAS Exon3 Conclusions EGFR mabs Cetuximab and panitumumab are interchangeable (see ASPECT trial results ECC 2013) Further molecular refinement of patient population beyond KRAS codon 12/13 essential To avoid detrimental effect of therapy To enrich patient population with better benefit/sideeffect margin More data on H2H cetuximab vs BEV will come from (RAS wt analysis!) At this point chemo + bevacizumab still viable option as first-line therapy in KRAS wt mcrc Don t use EGFR mabs in micrometastatic setting as long as we do not understand what is going on Optimized Treatment Strategy 67-year-old female Unresectable Lung and Liver Metastases Molecular testing Any RAS mut (60%) All RAS wt (40%) + CT doublet + CT doublet Regorafenib PD1 PD2 PD3 + CT doublet + CT doublet EGFR inhibitor +/- irinotecan EGFR inhibitor + CT doublet + CT doublet Regorafenib BSC PD4 Regorafenib BSC BSC 10
11 Advances in the Treatment of Stage IV CRC OS (months) BSC FU median overall survival Irinotecan Capecitabine Oxaliplatin Cetuximab Panitumumab Aflibercept Regorafenib BBP Mayo Clinic NP/PA and Consultants Old model NP/PAs have own calendars Supervised by consultants Patient has primary MD provider, but NP/PAs order chemotherapy, write scripts, and bill 1 st chemotherapy or change in therapy has to be cosigned by MD All study patient orders and forms have to be co-signed by MD New model NP/PAs share calendars with MDs Focus on team, not individual providers 11
12 A Collaborative Practice Approach to Managing Patients With Metastatic Colorectal Cancer: Update on Molecular Biomarkers to Guide Treatment Decisions Jackie Weatherly PA-C MD Anderson Cancer Center Colorectal Cancer Third most common newly diagnosed cancer Third most common cause of cancer death among US men and women Decreased incidence and death rates attributed to prevention and early detection through screening 96% are adenocarcinomas, majority arise from an adenomatous polyp Courtesy of the American Cancer Society Screening Flexible sigmoidoscopy every 5 years Colonoscopy every 10 years Fecal occult blood test annually 1
13 Risk Factors Heredity History of inflammatory bowel disease Obesity Smoking Diet Alcohol consumption Signs and Symptoms Rectal bleeding Change in stool/bowel habits Weight loss Abdominal pain Anemia Staging T1: Tumor invades submucosa T2: Tumor invades muscularis propria T3: Tumor invades through the muscularis propria into the subserosa or into nonperitonealized pericolic or pericolorectal tissues T4a: Tumor penetrates to the surface of the visceral peritoneum T4b: Tumor directly invades or is adherent to the other organs or structures N1a: Metastasis in 1 regional LN N1b: Metastasis in 2-3 regional LNs N1c: Tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional node mets N2a: Metastasis in 4-6 regional LNs N2b: Metastasis in 7 or more regional LNs M0: No distant mets M1a: Metastasis confined to one organ or site M1b: Metastasis in more than one organ/site or the peritoneum T1 T2 T3 T4a T4b N0 I I IIA IIB IIC N1 IIIA IIIA IIIB IIIB IIIC N2a IIIA IIIB IIIB IIIC IIIC N2b IIIB IIIB IIIC IIIC IIIC M1a IVA IVA IVA IVA IVA M1b IVB IVB IVB IVB IVB 2
14 FDA-Approved Systemic Agents, US Fluorouracil Irinotecan Capecitabine Oxaliplatin Adapted from Kelly, H. (2005). J Clin Oncol, 23, Cetuximab Panitumumab Regorafenib Aflibercept NCCN Guidelines: Advanced/MCRC 2014 Cetuximab and panitumumab are only recommended for patients with tumors that express the wild-type KRAS gene First Line Second Line Third Line FOLFOX + BEV or CapeOx + BEV FOLFIRI + FOLFOX ± panitumumab FOLFIRI + Cetuximab or Panitumumab 5-FU/LV + BEV FOLFIRI or Irinotecan + or Aflibercept FOLFIRI + Cetuximab or Cetuximab + Irinotecan FOLFOX or CapeOx + or Aflibercept or Cetuximab + Irinotecan FOLFOX or CapeOx + or Aflibercept Irinotecan or FOLFIRI + or Aflibercept Irinotecan + or Aflibercept + Irinotecan clinical trial or BSC + Irinotecan FOLFOX or CapeOx or Cetuximab + Irinotecan Fourth Line Poor tolerance to intensive therapy Capecitabine ± BEV or 5-FU + LV ± BEV Cetuximab or Panitumumab Improvement in functional status No improvement in functional status Therapy after first progression as above Best supportive care NCCN = National Comprehensive Cancer Network; BSC = best supportive care. Adapted from NCCN. (2014). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ). Colon cancer. Version Case Study 48 y/o woman presented with hematochezia and change in bowel habits Colonoscopy revealed cecal mass Right hemicolectomy
15 Pathology: Moderately differentiated adenocarcinoma of sigmoid polyp invading through the muscularis mucosa into the subserosal soft tissue, measuring cm. Tumor cells were immunopositive for MLH1, MSH2, PMS2, and MSH6. T3N0M0, MSI-high, Kras wild type No adjuvant therapy Staging T1: Tumor invades submucosa T2: Tumor invades muscularis propria T3: Tumor invades through the muscularis propria into the subserosa or into nonperitonealized pericolic or pericolorectal tissues T4a: Tumor penetrates to the surface of the visceral peritoneum T4b: Tumor directly invades or is adherent to the other organs or structures N1a: Metastasis in 1 regional LN N1b: Metastasis in 2-3 regional LNs N1c: Tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional node mets N2a: Metastasis in 4-6 regional LN N2b: Metastasis in 7 or more regional LN M0: No distant mets M1a: Metastasis confined to one organ or site M1b: Metastasis in more than one organ/site or the peritoneum T1 T2 T3 T4a T4b N0 I I IIA IIB IIC N1 IIIA IIIA IIIB IIIB IIIC N2a IIIA IIIB IIIB IIIC IIIC N2b IIIB IIIB IIIC IIIC IIIC M1a IVA IVA IVA IVA IVA M1b IVB IVB IVB IVB IVB Adjuvant Therapy Stage I: No adjuvant treatment Stage II q Microsatellite stable (MSS): Adjuvant therapy given based on other risk factors q MSI-H: No adjuvant therapy, associated with lower survival vs. surgery alone Stage III: 6 months adjuvant therapy 4
16 Overall Survival by MSI Ribic CM, et al.,(2003). New Engl J Med, 349, Case Study Continued 2011, admission for bowel obstruction CT showed peritoneal and liver metastases What would you do now? A. FOLFOX/bevacizumab B. FOLFOX C. FOLFIRI D. FOLFIRI/bevacizumab E. Irinotecan + cetuximab or panitumumab 5
17 NCCN Guidelines: Advanced/MCRC 2014 Cetuximab and panitumumab are only recommended for patients with tumors that express the wild-type KRAS gene First Line Second Line Third Line FOLFOX + BEV or CapeOx + BEV FOLFIRI + FOLFOX ± panitumumab FOLFIRI + Cetuximab or Panitumumab 5-FU/LV + BEV FOLFIRI or Irinotecan + or Aflibercept FOLFIRI + Cetuximab or Cetuximab + Irinotecan FOLFOX or CapeOx + or Aflibercept or Cetuximab + Irinotecan FOLFOX or CapeOx + or Aflibercept Irinotecan or FOLFIRI + or Aflibercept Irinotecan + or Aflibercept + Irinotecan clinical trial or BSC + Irinotecan FOLFOX or CapeOx or Cetuximab + Irinotecan Fourth Line Poor tolerance to intensive therapy Capecitabine ± BEV or 5-FU + LV ± BEV Cetuximab or Panitumumab Improvement in functional status No improvement in functional status Therapy after first progression as above Best supportive care NCCN = National Comprehensive Cancer Network; BSC = best supportive care. Adapted from NCCN. (2014). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ). Colon cancer. Version What would you do now? A. FOLFOX/bevacizumab B. FOLFOX C. FOLFIRI D. FOLFIRI/bevacizumab E. Irinotecan + cetuximab or panitumumab FOLFOX/ 17 mo 6
18 LV5FU2 + 6 mo Maintenance Therapy Proportion progression-free PFS 1.00 FOLFOX4 (median 9.0 mo) FOLFOX7 (median 8.7 mo) HR = 1.06 (95% CI, ) P = Proportion alive OS 1.00 FOLFOX4 (median 19.3 mo) FOLFOX7 (median 21.2 mo) HR = 0.93 (95% CI, ) P = Weeks Weeks Efficacy is similar between stop-and-go (FOLFOX7) and continuous (FOLFOX4) oxaliplatin CT regimens Tournigand, C., et al. (2006). J Clin Oncol, 24, Side effects Nausea/vomiting Pancytopenia Oxaliplatin Infusion-related reactions Neuropathy Sensitivity to cold Extravasation/pain and skin damage at site of injection Diarrhea 7
19 Side effects High blood pressure Proteinuria/nephrotic syndrome Infusion reaction Thromboembolism Wound dehiscence Gastrointestinal perforation Hemorrhage Case Study Continued CT showed progression of disease Resumed FOLFOX/bevacizumab Case Study Continued FOLFOX/bevacizumab 3 mo CT showed progression of disease 8
20 What would you do now? A. FOLFOX/bevacizumab B. FOLFOX C. FOLFIRI D. FOLFIRI/bevacizumab E. Irinotecan/cetuximab or panitumumab NCCN Guidelines: Advanced/MCRC 2014 Cetuximab and panitumumab are only recommended for patients with tumors that express the wild-type KRAS gene First Line Second Line Third Line FOLFOX + BEV or CapeOx + BEV FOLFIRI + FOLFOX ± panitumumab FOLFIRI + Cetuximab or Panitumumab 5-FU/LV + BEV FOLFIRI or Irinotecan + or Aflibercept FOLFIRI + Cetuximab or Cetuximab + Irinotecan FOLFOX or CapeOx + or Aflibercept or Cetuximab + Irinotecan FOLFOX or CapeOx + or Aflibercept Irinotecan or FOLFIRI + or Aflibercept Irinotecan + or Aflibercept + Irinotecan clinical trial or BSC + Irinotecan FOLFOX or CapeOx or Cetuximab + Irinotecan Fourth Line Poor tolerance to intensive therapy Capecitabine ± BEV or 5-FU + LV ± BEV Cetuximab or Panitumumab Improvement in functional status No improvement in functional status Therapy after first progression as above Best supportive care NCCN = National Comprehensive Cancer Network; BSC = best supportive care. Adapted from NCCN. (2014). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ). Colon cancer. Version What would you do now? A. FOLFOX/bevacizumab B. FOLFOX C. FOLFIRI D. FOLFIRI/bevacizumab E. Irinotecan/cetuximab or panitumumab 9
21 1.0 Chemotherapy (n=410) Bev + Chemotherapy (n=409) OS estimate Unstratified a HR: 0.81 (95% CI: ) p =.0062 (log-rank test) Stratified b HR: 0.83 (95% CI: ) p =.0211 (log-rank test) mo 11.2 mo Time (months) Bennouna, J., et al. (2013). Lancet Oncol, 14, FOLFIRI/ 4 mo Progression of disease Irinotecan Side effects Diarrhea Nausea/vomiting Pancytopenia Hair loss or thinning Fatigue 10
22 What would you do now? A. FOLFOX/bevacizumab B. Continue FOLFIRI/bevacizumab C. Irinotecan/cetuximab or panitumumab D. Regorafenib NCCN Guidelines: Advanced/MCRC 2014 Cetuximab and panitumumab are only recommended for patients with tumors that express the wild-type KRAS gene First Line Second Line Third Line FOLFOX + BEV or CapeOx + BEV FOLFIRI + FOLFOX ± panitumumab FOLFIRI + Cetuximab or Panitumumab 5-FU/LV + BEV FOLFIRI or Irinotecan + or Aflibercept FOLFIRI + Cetuximab or Cetuximab + Irinotecan FOLFOX or CapeOx + or Aflibercept or Cetuximab + Irinotecan FOLFOX or CapeOx + or Aflibercept Irinotecan or FOLFIRI + or Aflibercept Irinotecan + or Aflibercept + Irinotecan clinical trial or BSC + Irinotecan FOLFOX or CapeOx or Cetuximab + Irinotecan Fourth Line Poor tolerance to intensive therapy Capecitabine ± BEV or 5-FU + LV ± BEV Cetuximab or Panitumumab Improvement in functional status No improvement in functional status Therapy after first progression as above Best supportive care NCCN = National Comprehensive Cancer Network; BSC = best supportive care. Adapted from NCCN. (2014). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ). Colon cancer. Version What would you do now? A. FOLFOX/bevacizumab B. Continue FOLFIRI/bevacizumab C. Irinotecan/cetuximab or panitumumab D. Regorafenib 11
23 Case Study Continued Therapy changed to irinotecan/panitumumab 9 months Proportion with PFS Wild-type KRAS Subgroup: PFS by Treatment Events/N (%) Median (wk) Mean (wk) Pmab + BSC 115/124 (93) BSC Alone 114/119 (96) HR = 0.45 (95% CI: ) Stratified log-rank test, p < Weeks Amado, R. G., et al. (2008). J Clin Oncol, 26, CRYSTAL, by KRAS Van Cutsem, E., et al. (2008). Proc ASCO, Abstract 2. 12
24 Cetuximab and Panitumumab Side effects Infusion reaction Acneiform rash Diarrhea/constipation Low magnesium levels Sensitivity to sunlight Associated with risk for thromboembolic events Case Study Progressive disease Therapy changed to regorafenib Regorafenib Side effects Hand foot skin reaction (17%) Fatigue (10%) Hypertension (7%) Diarrhea (7%) Severe liver toxicity (0.3%) 13
25 Regorafenib Case Study 71 y/o woman initially diagnosed in 2003 with metastatic colon cancer to the liver s/p resection and adjuvant 5-FU Kras mutant Recurrence to the lung FOLFOX 8 cycles with PD FOLFIRI with PD Proportion with PFS Mutant KRAS Subgroup: PFS by Treatment Pmab + BSC BSC Alone Events/N (%) Median (wk) Mean (wk) 76/84 (90) /100 (95) HR = 0.99 (95% CI: ) Amado, R. G. (2008). J Clin Oncol, 26, Weeks Regorafenib Phase III CORRECT trial q 760 patients randomized to regorafenib vs placebo q Limited to good performance status (ECOG 0, 1) q OS 6.4 mo with regorafenib vs. 5 mo with placebo q PFS 1.9 mo vs. 1.7 mo Used on patients who have progressed on all other standard therapy/heavily pretreated 14
26 Progression-Free Survival Grothey, A. (2013). Lancet, 381, Overall Survival (Primary Endpoint) Grothey, A. (2013). Lancet, 381, Regorafenib Jan 2013 March 2013 CEA 29 CEA
27 May 2013 Regorafenib CEA 25.1 Thank you! 16
ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine
ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS Andrés Cervantes Professor of Medicine 1995 One option Advances in the treatment of mcrc 2000
More informationΚίκα Πλοιαρχοπούλου. Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών
Κίκα Πλοιαρχοπούλου Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών Time (months) Survival outcomes in mcrc have progressively improved over the past two decades Treatment options for many patients Multidisciplinary
More informationDoes it matter which chemotherapy regimen you partner with the biologic agents?
Does it matter which chemotherapy regimen you partner with the biologic agents? Yes, it does matter! Axel Grothey Disclosures Research Funding to MAYO Clinic Genentech Bayer Eisai Pfizer Imclone Potential
More informationConflicts of Interest GI Malignancies: An Update on Current Treatment Options
Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Nothing to disclose Trevor McKibbin, PharmD, MS, BCOP Clinical Specialist, Hematology/Oncology Winship Cancer Institute of
More informationFighting a Smarter War On Colon Cancer:
Fighting a Smarter War On Colon Cancer: Value as a new endpoint? John L. Marshall, MD Tel: (202) 444-0275 Fax: (202) 444-1229 http://lombardi.georgetown.edu/gi Stakeholder Motivation Stakeholders FDA CMS/Payers
More informationColon Cancer Molecular Target Agents
Colon Cancer Molecular Target Agents Ci Caio Max SR S. Rocha Lima, M.D. MD Professor of Medicine CDi CoDiretor Cl Colorectal tlheptobiliary, Pancreatic SDG, and Phase I Unit University of Miami & Silvester
More informationFirst line treatment in metastatic colorectal cancer
First line treatment in metastatic colorectal cancer Claus-Henning Köhne University Clinic Onkology and Haematology North West German Cancer Center (NWTZ) A non authorised version of ESMO guidelines was
More informationMETASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD
METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD INTRODUCTION Second leading cause of cancer related death in the United States. 136,830 cases in 2014
More informationState of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival
More informationWhat s New in Colon Cancer? Therapy over the last decade
What s New in Colon Cancer? 9/19/2014 Michael McNamara, MD Therapy over the last decade Cytotoxic chemotherapy - 5FU ( Mayo, Roswell, Infusional) - Xeloda (01 ) - Oxaliplatin (02 ) - Irinotecan (96 ) Anti-
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationToxicity by Age Group. Old Factor 1: Age. Disclosures. Predicting survival in metastatic colorectal cancer. Personalized Medicine - Decision Tools -
Disclosures Predicting survival in metastatic colorectal cancer Daniel Sargent, PhD Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis Genomic Health Personalized Medicine -
More informationTargeted and Chemotherapeutic Approaches to Management of Metastatic Colorectal Cancer. Nicole M. Ross, MSN, CRNP, AOCNP Fox Chase Cancer Center
Targeted and Chemotherapeutic Approaches to Management of Metastatic Colorectal Cancer Nicole M. Ross, MSN, CRNP, AOCNP Fox Chase Cancer Center Learning Objectives Critically evaluate current clinical
More informationTHE ROLE OF PREDICTIVE AND PROGNOSTIC MARKERS IN COLORECTAL CANCER
THE ROLE OF PREDICTIVE AND PROGNOSTIC MARKERS IN COLORECTAL CANCER Cathy Eng, M.D., F.A.C.P. Associate Professor Associate Medical Director, Colorectal Center Dept of GI Medical Oncology November 5, 2010
More informationColorectal Cancer Update Dr. Barb Melosky
Colorectal Cancer Update 2017 Dr. Barb Melosky bmelosky@bccancer.bc.ca Disclosure Research Support/P.I. Honoraria/Advisory Board Bayer Roche, Amgen, Bayer, Lilly Objectives 1) Demonstrate knowledge of
More informationJY Douillard MD, PhD Professor of Medical Oncology
ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Vienna 26-27 Program October 2015 Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer
More information2/20/14& Medical Management of Colon and Rectal Cancer: An Overview. Outline / Learning Objectives. How common is colon cancer?
Medical Management of Colon and Rectal Cancer: An Overview Jonathan Grim, MD, PhD VA Puget Sound Health Care System Fred Hutchinson Cancer Research Center UW Medicine Outline / Learning Objectives Epidemiology
More informationCetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer
Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer Cetuximab with Chemotherapy (CT) as First-Line Treatment for Metastatic Colorectal Cancer (mcrc): Analysis of
More informationAIOM GIOVANI Perugia, Luglio 2017
AIOM GIOVANI 2017 Perugia, 07-08 Luglio 2017 Scelta delle linee successive nel paziente RAS e BRAF wild-type con particolare accento su nuovi bersagli terapeutici Francesca Battaglin U.O.C. Oncologia Medica
More informationDALLA CAPECITABINA AL TAS 102
DALLA CAPECITABINA AL TAS 102 Milano 29 settembre 2016 LE PROSPETTIVE NELLA RICERCA Armando Santoro Humanitas Cancer Center THE 1,2.AND 3 LINE CHEMOTHERAPY IN CRC M BEVACIZUMAB AFLIBERCET RAS wt RAS mu
More informationChemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA
Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev
More informationWhat s New? Dr. Barbara Melosky
Metastatic Colorectal o Carcinoma a What s New? Dr. Barbara Melosky Objectives Review any recent changes regarding treatment t t options for mcrc Discuss the common and expected toxicities of treatment
More informationOPTIMISING OUTCOMES FOR PATIENTS WITH ADVANCED COLORECTAL CANCER
OPTIMISING OUTCOMES FOR PATIENTS WITH ADVANCED COLORECTAL CANCER E-Learning Module Stavros Gkolfinopoulos 1, Demetris Papamichael 1, George Pentheroudakis 2 1. Cyprus Oncology Centre, Nicosia, Cyprus 2.
More informationTHE CROSSROADS: Drug Development, Biomarkers, and Colorectal Cancer
THE CROSSROADS: Drug Development, Biomarkers, and Colorectal Cancer SANJAY GOEL, M.D., M.S. PROFESSOR OF MEDICINE ALBERT EINSTEIN COLLEGE OF MEDICINE MONTEFIORE MEDICAL CENTER DEPT. OF ONCOLOGY JUN 22,
More informationThird Line and Beyond: Management of Refractory Colorectal Cancer
Third Line and Beyond: Management of Refractory Colorectal Cancer George A. Fisher MD PhD Stanford University 1 Overview Defining the chemo refractory and intolerant Agents approved in 3 rd line setting
More informationJY Douillard MD, PhD Professor of Medical Oncology
Colorectal Cancer ESMO Preceptorship Program Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer Basic strategy and groups (RASwt/mut, BRAF mut) JY Douillard
More informationAshita Waterston Beatson West of Scotland Cancer Centre
Ashita Waterston Beatson West of Scotland Cancer Centre Aim of treatment Scheduling and choice of treatments are dictated by aim: Down staging for resectability: upfront intensive Prolong survival: combination
More informationCHEMOTHERAPY FOR COLON CANCER OUTLINE OF TODAY S TALK. Colon Cancer Epidemiology 11/6/2012 GATRA/GCCR FALL CONFERENCE NOVEMBER 14 16, 2012
CHEMOTHERAPY FOR COLON CANCER JONATHAN C. BENDER,MD MEDICAL DIRECTOR OF PIEDMONT FAYETTE CANCER CENTER OUTLINE OF TODAY S TALK 1. Overview of Colon Cancer in the US 2. Colon Cancer staging and risks of
More informationManaging mcrc Across Disease Continuum: Front-Line Therapy and Treatment Beyond Progression
Managing mcrc Across Disease Continuum: Front-Line Therapy and Treatment Beyond Progression Guillermo Méndez, MD Sección Oncología Hospital de Gastroenterología Bonorino Udaondo Carlos B. Udaondo y Fundación
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationColorectal Cancer Structured Pathology Reporting Proforma DD MM YYYY
Colorectal Cancer Structured Pathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.03). Family name Given name(s) Date of birth DD MM YYYY S1.02 Clinical details
More informationGastric and Colon Cancer. Dr. Andres Wiernik 2017
Gastric and Colon Cancer Dr. Andres Wiernik 2017 GASTRIC CANCER Gastric Cancer Classification Epidemiology General principles of Management 25% GE Junction Gastric Cancer 75% Gastric Cancer Epidemiology
More informationMetastatic Colorectal Cancer : The role of Personalised Medicine, Biomarkers and Early tumour shrinkage. Dr Lee-Ann Jones
Metastatic Colorectal Cancer : The role of Personalised Medicine, Biomarkers and Early tumour shrinkage Dr Lee-Ann Jones Aim Metastatic Colorectal Cancer: Past: 5FU, oxaliplatin, irinotecan..blanket treatment
More informationMÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO. Dra. Ruth Vera Complejo Hospitalario de Navarra
MÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO Dra. Ruth Vera Complejo Hospitalario de Navarra GOALS Prolongation of survival Cure Improving tumour-related symptoms Stopping tumour progression
More informationDr. Iain Tan. Senior Consultant GI Medical Oncologist National Cancer Centre Singapore
ESMO-ASIA 2017 Preceptorship (GI cancers) Session: Metastatic colorectal cancer, liver limited metastases Topic: Unresectable or borderline resectable : chemotherapy +/- targeted agents Dr. Iain Tan Senior
More informationKonzepte bei der Therapie des metastasierten kolorektalen Karzinoms
21. Ärzte Fortbildungskurs in Klinischer Onkologie 24.-26. Februar 2011 Kantonspital St. Gallen / Schweiz Konzepte bei der Therapie des metastasierten kolorektalen Karzinoms Claus-Henning Köhne Klinik
More informationIs it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS
Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS Survival Rates of by Stage of Adenocarcinoma of the Colon Liver Resection New Perspective Colorectal cancer liver
More informationReview of the ESMO consensus conference on metastatic CRC Basis strategies ad groups (RAS, BRAF, etc) Michel Ducreux
Review of the ESMO consensus conference on metastatic CRC Basis strategies ad groups (RAS, BRAF, etc) Michel Ducreux 2 ESMO consensus on mcrc 2016 Chairs: Co-Chairs of working groups E Van Cutsem A Sobrero
More informationIncorporating biologics in the management of older patients with metastatic colorectal cancer
Incorporating biologics in the management of older patients with metastatic colorectal cancer D Papamichael MB BS MD FRCP Cyprus Oncology Centre GSK Satellite Symposium SIOG APAC Singapore 12-13 July 2014
More informationTreatment of Advanced Colorectal Cancer
Treatment of Advanced Colorectal Cancer Alexis D. Leal, M.D. Assistant Professor, GI Medical Oncology University of Colorado Cancer Center Disclosures None Objectives Review the basics of advanced colorectal
More informationCOME HOME Innovative Oncology Business Solutions, Inc.
COME HOME Rectal Cancer Pathway V8, April 2015 Diagnostic Workup: Bethesda Criteria: Pathology Review All patients H&P All patients Biopsy All patients Colonoscopy All patients CEA All Patients Chest/Abdominal/Pelvic
More informationUnresectable or boarderline resectable disease
ESMO Preceptorship Colorectal Cancer Nov 2016 Barcelona Unresectable or boarderline resectable disease Claus-Henning Köhne Klinik für Onkologie und Hämatologie North West German Cancer Center (NWTZ) Learning
More informationStrategy for the treatment of metastatic CRC through the lines
Strategy for the treatment of metastatic CRC through the lines I Congresso de Oncologia D Or 2013: Satellite Symposium, ROCHE David Cosgrove, MD Johns Hopkins University Disclosures No relevant financial
More informationTumors in the Randomized German AIO study KRK-0306
FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First- Line Treatment for Patients with Metastatic Colorectal Cancer (mcrc): Analysis of Patients with KRAS-Mutated Tumors in the Randomized German
More informationCOMETS: COlorectal MEtastatic Two Sequences
COMETS: COlorectal MEtastatic Two Sequences A Phase III Multicenter Trial Comparing Two Different Sequences of Second/Third Line Therapy (Irinotecan/Cetuximab Followed By FOLFOX-4 vs. FOLFOX-4 Followed
More informationColon Cancer Update Christie J. Hilton, DO
POMA Winter Conference Christie Hilton DO Medical Oncology January 2018 None Colon Cancer Numbers Screening (brief update) Practice changing updates in colon cancer MSI Testing Immunotherapy in Colon Cancer
More informationChemotherapy of colon cancers
Chemotherapy of colon cancers Stage distribution Stage I : 15% T 1,2 NO Stage IV: 20 25% M+ Stage II : 20 30% T3,4 NO Stage III N+: 30 40% clinical stages I, II, or III colon cancer are at risk for having
More informationLa strategia terapeutica del carcinoma del colon metastatico
Dalla Capecitabina al TAS-102 Milano, 29 settembre 2016 La strategia terapeutica del carcinoma del colon metastatico Gianluca Masi U.O. di Oncologia Medica Universitaria Azienda Ospedaliero-Universitaria
More informationADVANCES IN COLON CANCER
ADVANCES IN COLON CANCER Peter T. Silberstein, M.D., FACP Professor, Creighton University Chief Hematology/Oncology UNIVERSAL SCREENING FOR LYNCH SYNDROME OF ALL PATIENTS WITH COLON CANCER ADOPTED BY CHI
More informationWhat to do after 1st-line failure in mcrc?
What to do after 1st-line failure in mcrc? Werner Scheithauer Univ.Klinik für Innere Med. I & CCC, Med.Uni.Wien-AKH mcrc front-line treatment strategy today Updated results of head-to-head trials in mcrc,
More informationADJUVANT CHEMOTHERAPY...
Colorectal Pathway Board: Non-Surgical Oncology Guidelines October 2015 Organization» Table of Contents ADJUVANT CHEMOTHERAPY... 2 DUKES C/ TNM STAGE 3... 2 DUKES B/ TNM STAGE 2... 3 LOCALLY ADVANCED
More informationManagement of Patients with Colorectal Cancer
Management of Patients with Colorectal Cancer Elsevier Office of Continuing Medical Education Independent Conference Highlights of the ASCO-GI 2018 Symposium Disclaimer The views expressed in the following
More informationNuevos Agentes en el Manejo de Cáncer Colorectal: Dónde Incorporalos?
Nuevos Agentes en el Manejo de Cáncer Colorectal: Dónde Incorporalos? Prof. Dr. Paulo M. Hoff Instituto do Câncer do Estado de São Paulo - ICESP Faculdade de Medicina Universidade de São Paulo (USP) Conflicts
More informationThe left versus right colon cancer story What is the truth?
The left versus right colon cancer story What is the truth? Prof. V. Heinemann CCC LMU, Klinikum Grosshadern Ludwig-Maximilian-University of Munich, Germany Three stages of truth (Schopenhauer) Ridicule
More informationRAS and BRAF in metastatic colorectal cancer management
Review Article RAS and BRAF in metastatic colorectal cancer management Jun Gong 1, May Cho 1, Marwan Fakih 2 1 Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA; 2 Medical
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationAdjuvant/neoadjuvant systemic treatment of colorectal cancer
5th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology Belgrade, June 19 th 2018 Adjuvant/neoadjuvant systemic treatment of colorectal cancer Carlotta Antoniotti Polo Oncologico
More informationDevelopment of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical modulation, Oral fluoropyrimidines, Developmentof combination chemotherapy
ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Valencia May Program 20-21st 2016 Prague May 22-23rd 2014 Development of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical
More informationColon cancer: Highlights. Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano
Colon cancer: Highlights Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano Agenda 1) Metastatic colorectal cancer First-line treatment molecularly unselected: FOLFOXIRI-bev (CHARTA trial) Later-line
More informationTherapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer
Therapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer Axel Grothey, M.D., Professor of Oncology, Clinical and Translational Science Division of Medical Oncology Mayo Clinic, Rochester,
More informationMANAGEMENT OF ADVANCED COLORECTAL CANCER
MANAGEMENT OF ADVANCED COLORECTAL CANCER Alberto Sobrero IRCCS San Martino IST Genoa Italy Disclosures : Pfizer, Roche, Merck, Amgen, Celgene, Bayer, Sanofi, Nordic, Takeda,BMS, Syrtex, Servier outline
More informationADVANCES IN COLORECTAL CANCERS IS THERE HOPE? Dr Lim Hwee Yong Medical Oncologist
ADVANCES IN COLORECTAL CANCERS IS THERE HOPE? Dr Lim Hwee Yong Medical Oncologist limhweeyong@live.com CRC: Epidemiology in 2012 Third most common cancer diagnosis in US [1] Estimated 143,460 new cases
More information1 st LINE ANTI-VEGF TREATMENT OF METASTATIC COLORECTAL CANCER (CRC)
1 st LINE ANTI-VEGF TREATMENT OF METASTATIC COLORECTAL CANCER (CRC) Role of the VEGF Pathway in Oncogenesis The Role of Angiogenesis in Cancer Somatic mutation Small avascular tumor Tumor secretion of
More informationCURRENT STANDARD OF CARE OF COLORECTAL CANCER: THE EVOLUTION OF ESMO CLINICAL PRACTICE GUIDELINES
CURRENT STANDARD OF CARE OF COLORECTAL CANCER: THE EVOLUTION OF ESMO CLINICAL PRACTICE GUIDELINES Fortunato Ciardiello ESMO Past-President 2018-2019 Dipartimento di Medicina di Precisione Università degli
More informationDisclosures. Clinical and molecular features to guide adjuvant therapy. Personalized Medicine - Decision Tools -
Disclosures Clinical and molecular features to guide adjuvant therapy Daniel Sargent Professor of Biostatistics & Oncology Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis
More informationWhat to do after 1 st line failure?
ESMO Preceptorship Programme Colorectal Cancer Singapore 20-22 nd 2016 JY Douillard MD PhD ESMO CMO What to do after 1 st line failure? mcrc: How to maximize survival? Improving 1st line therapy efficacy
More informationBRAF Testing In The Elderly: Same As in Younger Patients?
EGFR, K-RAS, K BRAF Testing In The Elderly: Same As in Younger Patients? Nadine Jackson McCleary MD MPH Gastrointestinal Oncology Dana-Farber/Harvard Cancer Care Boston, MA, USA Outline Colorectal cancer
More information2014/2015 FCDS Educational Webcast Series
2014/2015 FCDS Educational Webcast Series February 19, 2015 Steven Peace, CTR 2015 Update; Background, Anatomy, Risk Factors, Screening Guidelines, MPH Rules Review AJCC TNM 7 th ed, SS2000, CSv02.05 and
More informationPanitumumab: The KRAS Story. Chrissie Fletcher, MSc. BSc. CStat. CSci. Director Biostatistics, Amgen Ltd
Panitumumab: The KRAS Story Chrissie Fletcher, MSc. BSc. CStat. CSci. Director Biostatistics, Amgen Ltd Clinical Background: panitumumab in mcrc Panitumumab is a fully human IgG2 monoclonal antibody directed
More informationA Brief Overview of Screening and Management of Colorectal Cancer
A Brief Overview of Screening and Management of Colorectal Cancer Gentry King MD Assistant Professor Hematology and Medical Oncology University of Colorado Disclosures Nothing to disclose Objectives Review
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationCOLORECTAL CANCER CASES
COLORECTAL CANCER CASES Case #1 Case #2 Colorectal Cancer Case 1 A 52 year-old female attends her family physician for her yearly complete physical examination. Her past medical history is significant
More informationThe ESMO consensus conference on metastatic colorectal cancer
ESMO Preceptorship Programme Colorectal cancer Prague July, 6-7 2016 The ESMO consensus conference on metastatic colorectal cancer Andres Cervantes ESMO consensus on mcrc 2016 Chairs: Co-Chairs of working
More informationDisclosure. Nothing to Disclose Will not be discussing off label use of any of the medications
Disclosure Nothing to Disclose Will not be discussing off label use of any of the medications Where s Cranbrook? Follow Up of Colorectal Cancer Stage 0 (in-situ disease) and Stage I (T1-2 N0) Follow up
More informationColon cancer: ASCO poster review. Alfonso De Stefano MD, PhD SC Oncologia Clinica Sperimentale Addome
Colon cancer: ASCO poster review Alfonso De Stefano MD, PhD SC Oncologia Clinica Sperimentale Addome a.destefano@istitutotumori.na.it 255 poster examined: my selection Clinical Practice Translational &
More informationTargeting EGFR in Advanced Colorectal Cancer. Eric - Chen, MD, PhD
Targeting EGFR in Advanced Colorectal Cancer Eric - Chen, MD, PhD Outline Review of clinical data Kras and beyond Management of common side effects Alternative dosing regimens Treatment of Colorectal Cancer
More informationANTI-EGFR IN MCRC? Assoc. Prof. Gerald Prager, Medical University of Vienna, Austria
IS IT TIME TO RE-CHALLENGE ANTI-EGFR IN MCRC? Assoc. Prof. Gerald Prager, Medical University of Vienna, Austria Dr. Andrea Sartore-Bianchi, Oncologia Clinica Molecolare, Niguarda Cancer Center, Milano,
More informationAdvances in Chemotherapy of Colorectal Cancer
Advances in Chemotherapy of Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Disease Settings Adjuvant Therapy MOSAIC, FOLFOX Andre
More informationPerioperative chemotherapy for colorectal cancer livermetastases: what is the optimal strategy?
Perioperative chemotherapy for colorectal cancer livermetastases: what is the optimal strategy? Prof Eric Van Cutsem, MD, PhD Digestive Oncology Leuven, Belgium Eric.VanCutsem@uzleuven.be A classical case
More informationColorectal Cancer: Lumping or Splitting? Jimmy J. Hwang, MD FACP Levine Cancer Institute Carolinas HealthCare System Charlotte, NC
Colorectal Cancer: Lumping or Splitting? Jimmy J. Hwang, MD FACP Levine Cancer Institute Carolinas HealthCare System Charlotte, NC 2 Epidemiology Colorectal Cancer is the 2 nd Leading Cause of Cancer-related
More informationAdjuvant treatment Colon Cancer
ESMO Preceptorship Colorectal Cancer, October 2016 Singapore Adjuvant treatment Colon Cancer Claus-Henning Köhne University Clinic for Onkology und Haematology Oldenburg, Germany Aim of the lecture Adjuvant
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
information aligned with the expected toxicity profile of panitumumab, which is well-known as panitumumab is already used as a third-line therapy for patients with mcrc. perc also noted QoL did not deteriorate
More informationManagement Of Patients With Metastatic Colorectal Cancer in Lebanese Hospitals and Associated Direct Cost: A Multicenter Cohort Study
Management Of Patients With Metastatic Colorectal Cancer in Lebanese Hospitals and Associated Direct Cost: A Multicenter Cohort Study Henaine AM; Chahine G; Massoud M; Salameh P; Awada S; Lahoud N; El
More informationDaniele Santini University Campus Bio-Medico Rome, Italy
Daniele Santini University Campus Bio-Medico Rome, Italy Anti EGFR therapy and colorectal cancer Cetuximab or Panitumumab Adapted from Ciardiello F. and Tortora G. NEJM 2008;358:1160-74 Who will benefit
More informationTHE BEST OF ESMO 2016
THE BEST OF ESMO 2016 Colorectal cancer Pr Julien TAIEB, Sorbonne Paris Cité and Paris Descartes University Georges Pompidou European Hospital Paris, FRANCE esmo.org DISCLOSURES JT has received research
More informationASCO 2017 updates in Colorectal and Gastric Cancers. May Cho, M.D.
ASCO 2017 updates in Colorectal and Gastric Cancers May Cho, M.D. Relevant financial relationships in the past twelve months by presenter or spouse/partner: None The speaker will directly disclosure the
More informationMetastatic Colorectal Cancer. Update 2015
Metastatic Colorectal Cancer Update 2015 A/Prof Jeremy Shapiro GI Medical Oncologist Cabrini Hospital, Melbourne 1 Not all pts with metastatic CRC are equal 1 st consideration can patient be cured by resection
More informationHeavilyTreated mcrc..whats next?
ESMO Preceptorship Programme Gastrointestinal Cancer 20-22 October 2016,Singapore Dr Surendra Pal Chaudhary Dept of Medical Oncology Dr BR Ambedkar Instituite Rotary Cancer Hospital All India Institute
More informationMetastatik Kolorektal Kanser Tedavisinde Yeni Biyobelirteçler Sonrası Panitumumab. Prof. Dr. N. Faruk Aykan Antalya 22 Mart 2014
Metastatik Kolorektal Kanser Tedavisinde Yeni Biyobelirteçler Sonrası Panitumumab Prof. Dr. N. Faruk Aykan Antalya 22 Mart 2014 1952-1953 St. Louis, ABD Kinase growth factor pathway Activated receptor
More informationCOLORECTAL CANCER. Bert H. O Neil, MD Jackie and Joseph Cusick Professor of Oncology Director, GI Malignancies and Phase I Program
COLORECTAL CANCER Bert H. O Neil, MD Jackie and Joseph Cusick Professor of Oncology Director, GI Malignancies and Phase I Program Rectal Cancer Adjuvant therapy No single study specific to rectal cancer
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
of the clinical trial data for this outcome. Therefore, perc considered that the cost-effectiveness of cetuximab plus FOLFIRI would be at the higher end of the EGP s range of best estimates. Therefore,
More informationCASE STUDIES IN COLORECTAL CANCER: A ROUNDTABLE DISCUSSION
CASE STUDIES IN COLORECTAL CANCER: A ROUNDTABLE DISCUSSION PROVIDED AS AN EDUCATIONAL SERVICE BY THE INSTITUTE FOR CONTINUING HEALTHCARE EDUCATION SUPPORTED BY AN EDUCATIONAL GRANT FROM GENENTECH LEARNING
More informationNOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO
Congresso AIOM Giovani Perugia, 9 luglio 2016 NOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO Carlotta Antoniotti Polo Oncologico Azienda Ospedaliero-Universitaria Pisana Università di Pisa What
More informationTargeted therapies in colorectal cancer: the dos, don ts, and future directions
Editorial Targeted therapies in colorectal cancer: the dos, don ts, and future directions Marwan Fakih City of Hope Comprehensive Cancer Center, 1500 E Duarte St, Duarte, CA 91010, USA Corresponding to:
More informationMEET ROY*: A PATIENT WITH LIVER-LIMITED mcrc
MEET ROY*: A PATIENT WITH LIVER-LIMITED mcrc * A hypothetical case study of a patient eligible for first-line mcrc therapy. mcrc = metastatic colorectal cancer. WHAT CLINICAL CHARACTERISTICS AFFECT YOUR
More informationUnderstanding predictive and prognostic markers
Understanding predictive and prognostic markers Professor Aimery de Gramont Chairman of ARCAD Foundation and GERCOR, Paris FRANCE Understanding predictive and prognostic markers Aimery de Gramont Prognostic
More informationObjectives. Briefly summarize the current state of colorectal cancer
Disclaimer I do not have any financial conflicts to disclose. I will not be promoting any service or product. This presentation is not meant to offer medical advice and is not intended to establish a standard
More informationMSI and other molecular markers: how useful are they? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany
MSI and other molecular markers: how useful are they? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Disclosure slide I Member of advisory boards for AMGEN, ROCHE I Speaker
More informationThe role of Maintenance treatment Appropriate endpoints according to ESMO consensus
ESMO Preceptorship Programme Colorectal Cancer Singapore-October 20-22 2016 JY Douillard, MD, PhD, CMO ESMO The role of Maintenance treatment Appropriate endpoints according to ESMO consensus MAINTENANCE
More information